Coherent, Zeiss Supplying Lasers Free For Visudyne Treatment IND Study
This article was originally published in The Gray Sheet
Laser manufacturers Coherent and Zeiss are providing their device at no charge to physicians participating in Ciba Vision's treatment IND program for the photodynamic age-related macular degeneration treatment Visudyne (verteprofin).
You may also be interested in...
Coherent, Inc. and Zeiss Humphrey Systems are preparing to compete head-to-head for the placement of photodynamic therapy (PDT) lasers to perform "wet" age-related macular degeneration (AMD) therapy in conjunction with QLT PhotoTherapeutics' Visudyne (verteporfin for injection) pending imminent FDA approval for the combined drug/device treatment.
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.